rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CYTK
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Cytokinetics chief legal officer sells $794,877 in shares
      3h agoInvesting.comCYTK
      Cytokinetics at Jefferies: launch gains and label expansion
      Nov 17Investing.comCYTKJEF
      Cytokinetics Touts MYQORZO Launch Momentum, Plans New FDA Filing
      Nov 17Yahoo FinanceCYTK
      Cytokinetics stock hits 52-week low at $53.53
      Nov 16Investing.comCYTK
      Cytokinetics at UBS Global Biopharma Conference 2026: launch gains
      Nov 16Investing.comCYTK
      FDA approves label update for Cytokinetics’ heart drug MYQORZO
      Nov 16Investing.comCYTK
      Cytokinetics’ MYQORZO Gains Ground as Company Plans Push Into New Heart-Disease Market
      Nov 16Yahoo FinanceCYTK
      Cytokinetics director B. Lynne Parshall sells $273,634 in shares
      Nov 13Investing.comCYTK
      FDA Decision Watch: Summit’s Lung Cancer Drug, Cytokinetics’ Heart Therapy And Teva’s Igalmi In Spotlight This Week
      Nov 9Yahoo FinanceCYTKSMMTTEVA
      Cytokinetics' Myqorzo Could Inflect Revenue Starting 2027, RBC Capital Markets Says
      Nov 5Yahoo FinanceCYTK
      Cytokinetics stock hits 52-week low at 58.0 USD
      Nov 5Investing.comCYTK
      Cytokinetics, Incorporated Q3 2026 Earnings Call Summary
      Nov 5Yahoo FinanceCYTK
      Cytokinetics (CYTK) Could Be 41% Undervalued Following Strong Q3 And Aficamten Data

      Cytokinetics (CYTK) is back in focus after its third quarter update, with revenue of US$47.56 million, a narrower loss, and fresh late stage data for heart drug aficamten adding to the MYQORZO story. The third quarter update has arrived after a choppy stretch for Cytokinetics, with the share price falling 17.14% over the past 90 days but still showing a 3.03% year to date share price gain and a 5.47% total shareholder return over twelve months. At the current US$63.60 share price, that mix of...

      Nov 5Yahoo FinanceCYTK
      Cytokinetics Inc (CYTK) (Q3 2026) Earnings Call Highlights: Micorzo Launch Surges with 76% ...
      Nov 5Yahoo FinanceCYTK
      Cytokinetics Q3 Earnings Call Highlights
      Nov 5Yahoo FinanceCYTK
      Cytokinetics Q3 2026 Earnings Call Transcript
      Nov 4BenzingaCYTK
      Cytokinetics Q3 Loss Narrows, Revenue Rises
      Nov 4Yahoo FinanceCYTK
      Cytokinetics (CYTK) Reports Q3 Loss, Beats Revenue Estimates

      Cytokinetics (CYTK) delivered earnings and revenue surprises of +8.67% and +10.57%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

      Nov 4Yahoo FinanceCYTK
      Cytokinetics: Q3 Earnings Snapshot
      Nov 4Yahoo FinanceCYTK
      Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update
      Nov 4Yahoo FinanceCYTK
      Cytokinetics earnings up next: Can MYQORZO growth continue?
      Nov 4Investing.comCYTK
      Cytokinetics evp Fady Malik sells $220,255 in shares, exercises options
      Nov 3Investing.comCYTK
      Cytokinetics to Participate in November Investor Conferences
      Nov 3Yahoo FinanceCYTK
      Cytokinetics CEO Robert Blum sells $471,075 in CYTK stock
      Nov 3Investing.comCYTK
      Cytokinetics to Announce Third Quarter Results on November 4, 2026
      Oct 21Yahoo FinanceCYTK
      Cytokinetics EVP Fady Malik sells over $224,000 in stock
      Oct 21Investing.comCYTK
      Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The Product
      Oct 20Seeking AlphaCYTK
      Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Oct 19Yahoo FinanceCYTK
      BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says
      Oct 19Yahoo FinanceBBIOCYTK
      Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?
      Oct 19Yahoo FinanceCYTK
      BofA Securities Adjusts Price Target on Cytokinetics to $81 From $85, Maintains Neutral Rating
      Oct 19Yahoo FinanceCYTK
      Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
      Oct 19Yahoo FinanceCYTK
      William Blair Initiates Coverage on Cytokinetics With Outperform Rating
      Oct 16Yahoo FinanceCYTK
      William Blair initiates Cytokinetics stock coverage with outperform rating
      Oct 15Investing.comCYTK
      Here's How Much $1000 Invested In Cytokinetics 15 Years Ago Would Be Worth Today
      Oct 15BenzingaCYTK
      UBS cuts Cytokinetics stock price target on valuation, keeps Buy
      Oct 14Investing.comCYTK
      Cytokinetics Insider Sold Shares Worth $471,600, According to a Recent SEC Filing
      Oct 13Yahoo FinanceCYTK
      Aficamten’s ACACIA-HCM Multi-Domain Gains Might Change The Case For Investing In Cytokinetics (CYTK)
      Oct 13Yahoo FinanceCYTK
      Cytokinetics (CYTK), What Is Behind The Fresh Attention?
      Oct 13Yahoo FinanceCYTK
      Cytokinetics (CYTK) Stock Looks Hard To Pin Down Following Strong Heart Drug Updates
      Oct 13Yahoo FinanceCYTK
      Cytokinetics (CYTK) Reports Phase 3 Aficamten Gains In Non Obstructive HCM
      Oct 13Yahoo FinanceCYTK
      Cytokinetics presents additional aficamten data from trial
      Oct 12Investing.comCYTK
      Cytokinetics Q2 2026 Earnings Call: Complete Transcript - Cytokinetics (NASDAQ:CYTK)

      On Thursday, Cytokinetics (NASDAQ:CYTK) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial

      Oct 12BenzingaCYTK
      Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
      Oct 12Yahoo FinanceCYTK
      Cytokinetics EVP Fady Malik sells $214,830 in company stock
      Oct 11Investing.comCYTK
      RBC Lifts Price Target on Cytokinetics to $113 From $112, Keeps Outperform Rating
      Oct 8Yahoo FinanceCYTK
      Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
      Oct 2Yahoo FinanceCYTK
      Cytokinetics launches real-world study of heart drug MYQORZO
      Sep 30Investing.comCYTK
      Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy

      Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical Practice SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the start of ASPEN-HCM (Aficamten Study of Patient Experience and Novel Outcomes in Symptomatic Obstructive HCM), a prospective, multicenter, observational real-world study evaluating MYQORZO® (aficamten) in adult patients w

      Sep 30Yahoo FinanceCYTK
      Cytokinetics CEO Robert Blum sells $490,949 in stock
      Sep 29Investing.comCYTK

      This is the newest page. Registered accounts read further back.